$VIVO (Meridian Bioscience, Inc.)

$VIVO {{ '2015-11-13T10:27:45+0000' | timeago}} • Announcement

Producer and distributor of diagnostic test kits $VIVO said that it has made an investment in Oasis Diagnostics Corporation, which develops, manufactures and sells pre-analytic tools. The intend of the investment by $VIVO in Oasis is to acquire it in future. The terms of the transaction were not disclosed.

$VIVO {{ '2017-10-19T17:11:02+0000' | timeago}} • Announcement

For FY18, $VIVO expects revenue of $207-212MM, representing growth of 3-6%.  The company sees GAAP EPS of $0.59-0.62 and non-GAAP EPS of $0.65-0.68. The company is increasing its focus on investments in R&D and sales and marketing. $VIVO expects the increased investments in these areas to drive higher revenue levels in FY18.

$VIVO {{ '2017-10-19T17:06:44+0000' | timeago}} • Announcement

$VIVO expects FY17 revenue of about $200.5MM, an increase of 2% compared to the prior year. The company predicts GAAP EPS of $0.50-0.51 and non-GAAP EPS of $0.66-0.67 for FY17. For 4Q17, $VIVO sees revenue of about $49.5MM, representing 5% growth compared to the prior year.

$VIVO {{ '2017-10-10T16:19:48+0000' | timeago}} • Announcement

$VIVO has appointed John P. Kenny as CEO, effective October 9, 2017. He has also been appointed to $VIVO’s BoD effective October 9, 2017. Mr. Kenny comes to $VIVO from Siemens Healthcare. Concurrent with the hiring of Mr. Kenny, John A. Kraeutler, CEO & Chairman of the Board, steps down as CEO and takes the title of Executive Chairman.

$VIVO {{ '2017-09-05T18:48:26+0000' | timeago}} • Announcement

$VIVO's subsidiary, Meridian Life Science, Inc., announced the launch of TRU Block ULTRA. The advantage of TRU Block ULTRA is its active blocking technology across various assay types and its powerful assay interference blocking against human anti-mouse antibodies (HAMA), rheumatoid factor (RH), and heterophilic antibodies (HA).

$VIVO {{ '2017-08-09T18:24:11+0000' | timeago}} • Announcement

$VIVO has initiated clinical trials for a new illumigene CMV molecular amplification test. This assay is designed to specifically detect the congenital Cytomegalovirus (CMV) infection in newborns from saliva. Presently, there is no FDA-cleared test for CMV screening in newborns.

$VIVO {{ '2017-08-08T18:59:58+0000' | timeago}} • Announcement

$VIVO has expanded its ImmunoCard STAT! product line with the addition of ImmunoCard STAT! FLU A&B. ImmunoCard STAT! FLU A&B detects the presence of influenza A & B in nasal and nasopharyngeal swabs and can also be used to test aspirates and nasal washes.

$VIVO {{ '2017-08-08T16:07:28+0000' | timeago}} • Announcement

Life science company $VIVO has appointed John M Rice as an independent director of its BoD, effective August 8, 2017. Rice, who is the founder of venture capital firm Triathlon Medical Venture Partners, has been serving as the Director of Life Sciences at CincyTech since 2003.

$VIVO {{ '2017-06-30T16:33:27+0000' | timeago}} • Announcement

$VIVO provided clarifying comments regarding a June 29, 2017 letter from a group of U.S. Senators to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). The letter pertains to venous blood lead testing performed on the systems produced by $VIVO's subsidiary Magellan Diagnostics.

$VIVO {{ '2017-05-17T19:50:58+0000' | timeago}} • Announcement

$VIVO said its subsidiary Magellan Diagnostics is currently working with the U.S. Food and Drug Administration (FDA) regarding use of venous blood with its LeadCare Testing Systems. Magellan’s primary product is LeadCare II, a point-of-care blood lead testing system, on which the vast majority of tests are performed with capillary blood samples.

$VIVO {{ '2017-05-10T14:37:15+0000' | timeago}} • Announcement

$VIVO will commence a search for a new CEO in conjunction with the planned retirement of John Kraeutler.  Kraeutler plans to continue to serve until his successor is found. He will assist the new CEO during the transition and onboarding phases, and will remain as Executive Chairman of Meridian's BoD.

$VIVO {{ '2017-03-08T17:20:18+0000' | timeago}} • Announcement

$VIVO said its business unit Magellan Diagnostics signed an exclusive distribution agreement with Biofirm Technologies. Magellan Diagnostics' LeadCare II blood lead testing system is the only FDA cleared, rapid and portable system capable of providing a quantitative blood lead result in just three minutes.

$VIVO {{ '2016-12-20T19:13:08+0000' | timeago}} • Announcement

$VIVO said its Magellan Diagnostics business unit has signed an exclusive distribution agreement with MedCaptain Medical Technology to expand blood lead testing in China. LeadCare II is used in thousands of pediatric and primary care settings in the United States to help doctors diagnose lead exposure quickly and easily.

$VIVO {{ '2016-10-19T17:03:47+0000' | timeago}} • Announcement

$VIVO expects FY17 net revenue of $205-210MM, representing 5-7% growth, and EPS of $0.81-0.85, representing 1-8% growth. The EPS forecast excludes costs associated with acquisition activities and the reorganization of sales and marketing leadership in 2016 and assumes rise in average shares outstanding to about 42.6MM at year-end FY17.

$VIVO {{ '2016-10-19T17:00:35+0000' | timeago}} • Announcement

$VIVO expects FY16 revenue of about $196MM, an increase of 1% from prior year, and EPS of $0.75-0.76. The EPS forecast includes costs related to acquisition activity and costs associated with the reorganization of Diagnostics sales and marketing leadership. The preliminary results reflect 4Q revenues of about $47MM.

$VIVO {{ '2016-09-26T18:20:53+0000' | timeago}} • Announcement

Life sciences company $VIVO amended its license agreement with Eiken Chemical Co., Ltd. for its Loop-mediated Isothermal Amplification (LAMP) technology for the areas of animal, food and water testing. The new agreement allows $VIVO to use the LAMP technology to detect infectious agents causing disease in animals or contaminants in food or water.

$VIVO {{ '2016-06-15T17:22:29+0000' | timeago}} • Announcement

$VIVO said it has received FDA clearance for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and improved illumigene Mycoplasma Direct assay, launched earlier this year in Europe, features simplified 3-step procedure.

$VIVO {{ '2016-04-27T13:12:57+0000' | timeago}} • Announcement

$VIVO said it has received the CE Mark for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and improved illumigene Mycoplasma Direct assay features a simplified procedure compared to the existing illumigene Mycoplasma product.

$VIVO {{ '2016-03-24T20:28:03+0000' | timeago}} • Announcement

Life science technology company $VIVO said that it acquired Magellan Biosciences, Inc. and its wholly owned subsidiary Magellan Diagnostics, Inc. The company expects Magellan to contribute to EPS during calendar 2H17. $VIVO will finance the purchase price of $66MM using a combination of cash on hand and a $60MM five-year term loan.

$ILMN {{ '2015-12-10T11:49:01+0000' | timeago}} • Announcement

$VIVO's Bioline announced the worldwide release of the JetSeq DNA Library Preparation Kit. Developed in collaboration with Oxford Gene Technology, the Kit uses highly optimized enzymes and buffers to enable the preparation of the highest quality Next Generation Sequencing-ready, adapter-ligated DNA for $ILMN's next-generation sequencers.

$VIVO {{ '2015-11-18T19:05:31+0000' | timeago}} • Announcement

Clinical diagnostic kits maker $VIVO said it has received clearance from FDA for new illumigene Pertussis molecular amplification test claims, which reduces the effect of inhibitors in biologic samples. This test expands Company's customer base by including specimens collected by ESwab, a liquid-based collection and transport system.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, January 16 2018 - 1:45pm
NEOG (Neogen Corp.)
Wednesday, January 3 2018 - 4:00pm
IMMU (Immunomedics Inc.)
Thursday, November 9 2017 - 10:00pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
HOLX (Hologic Inc.)
Wednesday, November 8 2017 - 9:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
MYGN (Myriad Genetics, Inc.)
Tuesday, November 7 2017 - 9:30pm
QGEN (Qiagen NV)
Tuesday, November 7 2017 - 2:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
BIO.B (Bio-Rad Laboratories, Inc.)
Thursday, November 2 2017 - 9:00pm
GNMK (GenMark Diagnostics, Inc.)
Thursday, November 2 2017 - 8:30pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
QDEL (Quidel Corp.)
Wednesday, November 1 2017 - 9:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
QTNT (Quotient Limited)
Tuesday, October 31 2017 - 12:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
OXFD (Oxford Immunotec Global PLC)
Tuesday, October 31 2017 - 12:00pm
TRIB (Trinity Biotech plc)
Thursday, October 26 2017 - 3:00pm

AlphaGraphics you may like